Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Immutep Ltd ( (AU:IMM) ).
Immutep Ltd has announced the issuance of 4,055,555 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) starting October 1, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially strengthen its market position, offering stakeholders an opportunity to invest in its growth and development.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd operates in the biotechnology industry, focusing on developing immunotherapy treatments. The company is known for its work on innovative therapies aimed at modulating the immune system to treat cancer and autoimmune diseases.
Average Trading Volume: 2,438,246
Technical Sentiment Signal: Sell
Current Market Cap: A$381.6M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.